PharmAbcine Inc.

KOSDAQ:A208340 Stock Report

Market Cap: ₩9.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PharmAbcine Past Earnings Performance

Past criteria checks 2/6

PharmAbcine has been growing earnings at an average annual rate of 37.4%, while the Biotechs industry saw earnings growing at 23.3% annually. Revenues have been growing at an average rate of 92.9% per year. PharmAbcine's return on equity is 2.3%, and it has net margins of 7.5%.

Key information

37.44%

Earnings growth rate

45.98%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate92.87%
Return on equity2.25%
Net Margin7.45%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Analysis Article • Jan 23

Take Care Before Diving Into The Deep End On PharmAbcine Inc. (KOSDAQ:208340)

With a price-to-sales (or "P/S") ratio of 0.9x PharmAbcine Inc. ( KOSDAQ:208340 ) may be sending very bullish signals...
Analysis Article • Mar 29

PharmAbcine (KOSDAQ:208340) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 14

Health Check: How Prudently Does PharmAbcine (KOSDAQ:208340) Use Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Revenue & Expenses Breakdown

How PharmAbcine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A208340 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2515,1901,1325,5423,900
30 Jun 255,741-4,1514,5924,345
31 Mar 255,741-4,1514,3374,510
31 Dec 243,886-4,9244,1395,019
30 Sep 24106-4,4965884,861
30 Jun 24113-6,1065635,663
31 Mar 24113-11,3843,3265,746
31 Dec 2375-14,2473,8907,809
30 Sep 23146-24,3943,9559,829
30 Jun 23175-24,3697,7917,472
31 Mar 23185-27,8574,44215,462
31 Dec 22207-30,5484,26718,928
30 Sep 2290-24,0544,15920,203
30 Jun 2255-33,48757433,567
31 Mar 2245-34,4184,40532,883
31 Dec 2168-44,0334,31833,686
30 Sep 21100-46,9294,55536,609
30 Jun 21110-43,3324,56128,750
31 Mar 21110-41,3394,36724,410
31 Dec 2060-30,6785,26820,183
30 Sep 2010-22,6464,90016,066
30 Jun 200-29,1144,52012,491
31 Mar 200-13,9034,0488,412
31 Dec 190-10,1582,7127,288
30 Sep 190-14,3065,0705,211
30 Jun 1901,1604,7353,657
31 Mar 192-7,6014,5443,331
31 Dec 182-6,9764,3152,587
31 Dec 17209-6,4831,3012,436

Quality Earnings: A208340 has a large one-off gain of ₩2.3B impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: A208340 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A208340 has become profitable over the past 5 years, growing earnings by 37.4% per year.

Accelerating Growth: A208340 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A208340 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (44.3%).

Return on Equity

High ROE: A208340's Return on Equity (2.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 22:17
End of Day Share Price 2026/01/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmAbcine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.